These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9046337)

  • 61. 6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1995 May; 38(10):1778-85. PubMed ID: 7752201
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Hynes JB; Queener SF
    Antimicrob Agents Chemother; 1995 Jan; 39(1):79-86. PubMed ID: 7695334
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Kinetic and structural analysis for potent antifolate inhibition of Pneumocystis jirovecii, Pneumocystis carinii, and human dihydrofolate reductases and their active-site variants.
    Cody V; Pace J; Queener SF; Adair OO; Gangjee A
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2669-77. PubMed ID: 23545530
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent.
    Allegra CJ; Kovacs JA; Drake JC; Swan JC; Chabner BA; Masur H
    J Exp Med; 1987 Mar; 165(3):926-31. PubMed ID: 2950200
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs.
    Itoh F; Yoshioka Y; Yukishige K; Yoshida S; Ootsu K; Akimoto H
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1270-80. PubMed ID: 10993224
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities.
    Gangjee A; Zaveri N; Kothare M; Queener SF
    J Med Chem; 1995 Sep; 38(18):3660-8. PubMed ID: 7658454
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 2,4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition.
    Algul O; Paulsen JL; Anderson AC
    J Mol Graph Model; 2011 Feb; 29(5):608-13. PubMed ID: 21146434
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dihydrofolate reductase from the pathogenic fungus Pneumocystis carinii: catalytic properties and interaction with antifolates.
    Margosiak SA; Appleman JR; Santi DV; Blakley RL
    Arch Biochem Biophys; 1993 Sep; 305(2):499-508. PubMed ID: 8373187
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation.
    Reynolds RC; Campbell SR; Fairchild RG; Kisliuk RL; Micca PL; Queener SF; Riordan JM; Sedwick WD; Waud WR; Leung AK; Dixon RW; Suling WJ; Borhani DW
    J Med Chem; 2007 Jul; 50(14):3283-9. PubMed ID: 17569517
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
    Hopper AT; Brockman A; Wise A; Gould J; Barks J; Radke JB; Sibley LD; Zou Y; Thomas S
    J Med Chem; 2019 Feb; 62(3):1562-1576. PubMed ID: 30624926
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis.
    Mattioni BE; Jurs PC
    J Mol Graph Model; 2003 Mar; 21(5):391-419. PubMed ID: 12543137
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of dihydrofolate reductases from Toxoplasma gondii, Pneumocystis carinii, and rat liver by rotationally restricted analogues of pyrimethamine and metoprine.
    Rosowsky A; Queener SF; Cody V
    Drug Des Discov; 1999 Jul; 16(1):25-40. PubMed ID: 10466054
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A review of molecular modelling studies of dihydrofolate reductase inhibitors against opportunistic microorganisms and comprehensive evaluation of new models.
    Tawari NR; Bag S; Degani MS
    Curr Pharm Des; 2011; 17(7):712-51. PubMed ID: 21395543
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: design, synthesis and antifolate activity.
    Zhang Z; Wu J; Ran F; Guo Y; Tian R; Zhou S; Wang X; Liu Z; Zhang L; Cui J; Liu J
    Eur J Med Chem; 2009 Feb; 44(2):764-71. PubMed ID: 18555562
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
    Richardson ML; Croughton KA; Matthews CS; Stevens MF
    J Med Chem; 2004 Jul; 47(16):4105-8. PubMed ID: 15267250
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
    da Cunha EF; Ramalho TC; Reynolds RC
    J Biomol Struct Dyn; 2008 Feb; 25(4):377-85. PubMed ID: 18092832
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.
    Cody V; Pace J; Rosowsky A
    Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):977-84. PubMed ID: 18703847
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
    Chan DC; Laughton CA; Queener SF; Stevens MF
    J Med Chem; 2001 Aug; 44(16):2555-64. PubMed ID: 11472209
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
    Graffner-Nordberg M; Kolmodin K; Aqvist J; Queener SF; Hallberg A
    Eur J Pharm Sci; 2004 May; 22(1):43-54. PubMed ID: 15113582
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of Pneumocystis carinii dihydrofolate reductase.
    Santos-Filho OA; Forge D; Hoelz LV; de Freitas GB; Marinho TO; Araújo JQ; Albuquerque MG; de Alencastro RB; Boechat N
    J Mol Model; 2012 Sep; 18(9):4061-72. PubMed ID: 22527273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.